Physician profile
Robert E Tamayo
NPI 1225114713
$1,717.69
in general payments reported to CMS, 2019-2025
12 companies · $582 in 2025
The $582 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $97.80 · 2021: $198 · 2022: $160 · 2023: $78.75 · 2024: $464 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003 · Entertainment: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.54 |
| Entertainment | $122.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $458.32 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Optos, INC. | $443.65 | 2021-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Alcon Vision LLC | $216.44 | 2020-2024 | Precision 1, Dailies Total1, Total30 |
| Lkc Technologies, INC. | $120.38 | 2025 | |
| Abb Con-Cise Optical Group LLC | $101.36 | 2024 | Contact Lens, Spectacle Lenses |
| Johnson & Johnson Vision Care, INC. | $94.40 | 2023-2025 | Acuvue |
| Visioneering Technologies, INC. | $92.26 | 2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $67.48 | 2019 | |
| Bausch & Lomb Americas INC. | $48.52 | 2023 | Infuse |
| Ge Healthcare | $37.95 | 2025 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Sight Sciences, INC. | $17.53 | 2025 | Tearcare System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tamayo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.